709 related articles for article (PubMed ID: 8614385)
21. [The Munich study on the treatment of acute lymphoblastic leukemia in childhood (ALL 77-02)].
Graubner UB; Haas RJ; Janka G; Gaedicke G; Kohne E; Rieber EP
Klin Padiatr; 1985; 197(3):207-14. PubMed ID: 3892149
[TBL] [Abstract][Full Text] [Related]
22. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
[TBL] [Abstract][Full Text] [Related]
23. Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.
Feig SA; Ames MM; Sather HN; Steinherz L; Reid JM; Trigg M; Pendergrass TW; Warkentin P; Gerber M; Leonard M; Bleyer WA; Harris RE
Med Pediatr Oncol; 1996 Dec; 27(6):505-14. PubMed ID: 8888809
[TBL] [Abstract][Full Text] [Related]
24. [Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].
Derwich K; Wachowiaki J; Kaczmarek-Kanoldi M; Balcerska A; Balwierz W; Chybicka A; Kowalczyk JR; Matysiak M; Jackowska T; Sońta-Jakimczyk D; Wysocki M; Chełmecka-Hanuszewicz L; Cwiklińska M; Kołtan A; Malinowska I; Odój T; Płoszyńska A; Steczowicz M; Wojciechowska V; Wójtowicz A;
Przegl Lek; 2006; 63(1):7-10. PubMed ID: 16892891
[TBL] [Abstract][Full Text] [Related]
25. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
[TBL] [Abstract][Full Text] [Related]
26. Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience.
Moe PJ; Holen A; Nygaard R; Glomstein A; Madsen B; Hellebostad M; Stokland T; Wefring KW; Steen-Johnsen J; Nielsen B; Hapnes C; Børsting S
Pediatr Hematol Oncol; 2003; 20(3):187-200. PubMed ID: 12637215
[TBL] [Abstract][Full Text] [Related]
27. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
28. Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.
Spiegler BJ; Kennedy K; Maze R; Greenberg ML; Weitzman S; Hitzler JK; Nathan PC
J Clin Oncol; 2006 Aug; 24(24):3858-64. PubMed ID: 16921038
[TBL] [Abstract][Full Text] [Related]
29. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
[TBL] [Abstract][Full Text] [Related]
30. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.
Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L
J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483
[TBL] [Abstract][Full Text] [Related]
31. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
[TBL] [Abstract][Full Text] [Related]
32. Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia: A Report from Children's Cancer Study Group.
Nesbit ME; Sather H; Robison LL; Donaldson M; Littman P; Ortega JA; Hammond GD
Cancer Res; 1982 Feb; 42(2):674-80. PubMed ID: 7034927
[TBL] [Abstract][Full Text] [Related]
33. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial.
Laver JH; Kraveka JM; Hutchison RE; Chang M; Kepner J; Schwenn M; Tarbell N; Desai S; Weitzman S; Weinstein HJ; Murphy SB
J Clin Oncol; 2005 Jan; 23(3):541-7. PubMed ID: 15659500
[TBL] [Abstract][Full Text] [Related]
34. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
35. Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
Chiu EK; Chan LC; Liang R; Lie A; Kwong YL; Todd D; Chan TK
Leukemia; 1994 Sep; 8(9):1469-73. PubMed ID: 8090027
[TBL] [Abstract][Full Text] [Related]
36. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer S; Steuber CP; Camitta B
J Clin Oncol; 2000 Mar; 18(6):1285-94. PubMed ID: 10715299
[TBL] [Abstract][Full Text] [Related]
37. [Acute lymphoblastic leukemia in children with initial leucocytosis above 50,000/mm3: summary of treatment results of Polish Pediatric Leukemia/Lymphoma Study Group].
Skoczeń S; Balwierz W; Moryl-Bujakowska A; Pawińska K; Luszczyńska A; Balcerska A; Płoszyńska A; Chybicka A; Dobaczewski G; Juszczak K; Wachowiak J; Derwich K; Kowalczyk J; Wiśniewska-Slusarz H; Matysiak M; Krauze A; Pawelec K; Sońta-Jakimczyk D; Tomaszewska R; Wysocki M; Styczyńskii J; Swiatkiewicz V;
Przegl Lek; 2006; 63(1):11-4. PubMed ID: 16892892
[TBL] [Abstract][Full Text] [Related]
38. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
39. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study.
Barredo JC; Devidas M; Lauer SJ; Billett A; Marymont M; Pullen J; Camitta B; Winick N; Carroll W; Ritchey AK
J Clin Oncol; 2006 Jul; 24(19):3142-9. PubMed ID: 16809737
[TBL] [Abstract][Full Text] [Related]
40. B-lineage acute lymphoblastic leukemia of childhood. An institutional experience.
Rivera-Luna R; Cardenas-Cardos R; Leal-Leal C; Navarro-Alegría I; Meza-Coria C; Gómez-Martínez R; Vega-Vega L
Arch Med Res; 1997; 28(2):233-9. PubMed ID: 9204615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
